In MR analysis, we found that SGLT2 inhibition was associated with reduced risk of T2DM (odds ratio [OR] = 0.63 [95% CI 0.45, 0.88], P = 0.006) and AF (0.51 [0.27, 0.97], P = 0.039), for per 1 SD lowering of HbA1c via SGLT2 inhibition (Table 1). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.